Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO

Sponsor
Mie University
Study ID
NCT02091505
Status
Unknown

Conditions

  • Central Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
20 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Recent studies have shown that intravitreal injection of anti-VEGF agent, Lucentis (Ranibizumab) is effective for macular edema associated with central retinal vein occlusion (CRVO). However, there is little information on whether there are any predictive factors of treatment outcome after this treatment. We plan to perform comprehensive functional and imaging tests to determine significant predictive factors.

Key Dates

First listed
Mar 19, 2014
Start date
Dec 31, 2013
Status verified
Mar 2014
Primary completion
May 31, 2016

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intravitreal injection of Ranibizumab

Primary Outcome Measure

Best-corrected visual acuity [ Time Frame: 12 months ]

Central Contacts